{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T02:23:59Z","timestamp":1774837439241,"version":"3.50.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11886-019-1175-z","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T03:37:32Z","timestamp":1564976252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options"],"prefix":"10.1007","volume":"21","author":[{"given":"Adam N.","family":"Berman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Blankstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"issue":"10159","key":"1175_CR1","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","unstructured":"GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736\u201388.","journal-title":"Lancet"},{"key":"1175_CR2","unstructured":"Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief. 2018(328):1\u20138."},{"key":"1175_CR3","first-page":"E157","volume":"13","author":"HK Weir","year":"2016","unstructured":"Weir HK, Anderson RN, Coleman King SM, Soman A, Thompson TD, Hong Y, et al. Heart disease and cancer deaths - trends and projections in the United States, 1969-2020. Prev Chronic Dis. 2016;13:E157.","journal-title":"Prev Chronic Dis"},{"issue":"0","key":"1175_CR4","first-page":"CIR000000000000","volume":"0","author":"SM Grundy","year":"2018","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol. Circulation. 2018;0(0):CIR0000000000000625.","journal-title":"Circulation."},{"issue":"10","key":"1175_CR5","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56\u2013e528.","journal-title":"Circulation."},{"issue":"4","key":"1175_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","volume":"121","author":"DM Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association\u2019s strategic impact goal through 2020 and beyond. Circulation. 2010;121(4):586\u2013613.","journal-title":"Circulation."},{"issue":"6","key":"1175_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743\u201353.","journal-title":"Circulation."},{"issue":"11","key":"1175_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"RM Conroy","year":"2003","unstructured":"Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987\u20131003.","journal-title":"Eur Heart J"},{"issue":"25 Pt B","key":"1175_CR9","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB Sr, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935\u201359.","journal-title":"J Am Coll Cardiol"},{"issue":"0","key":"1175_CR10","first-page":"CIR000000000000","volume":"0","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;0(0):CIR0000000000000678.","journal-title":"Circulation."},{"issue":"39","key":"1175_CR11","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J"},{"issue":"0","key":"1175_CR12","first-page":"CIR000000000000","volume":"0","author":"DM Lloyd-Jones","year":"2018","unstructured":"Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS, Virani SS, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease. Circulation. 2018;0(0):CIR0000000000000638.","journal-title":"Circulation."},{"issue":"10","key":"1175_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jacc.2014.06.1186","volume":"64","author":"KN Karmali","year":"2014","unstructured":"Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC\/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64(10):959\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1175_CR14","first-page":"598","volume":"38","author":"AP DeFilippis","year":"2017","unstructured":"DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, Kronmal RA, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38(8):598\u2013608.","journal-title":"Eur Heart J"},{"issue":"3","key":"1175_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jacc.2017.11.007","volume":"71","author":"A Singh","year":"2018","unstructured":"Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, et al. Cardiovascular risk and statin eligibility of young adults after an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018;71(3):292\u2013302.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1175_CR16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","volume":"66","author":"K Nasir","year":"2015","unstructured":"\u2022\u2022 Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657\u201368 This important analysis underscores the utility of coronary artery calcium testing in accurately classifying ASCVD risk.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1175_CR17","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jcmg.2017.04.014","volume":"10","author":"JC Hong","year":"2017","unstructured":"Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, et al. Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC\/AHA cholesterol management guidelines: a cost-effectiveness analysis. JACC Cardiovasc Imaging. 2017;10(8):938\u201352.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"1175_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/CIRCOUTCOMES.113.000799","volume":"7","author":"MJ Pletcher","year":"2014","unstructured":"Pletcher MJ, Pignone M, Earnshaw S, McDade C, Phillips KA, Auer R, et al. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2014;7(2):276\u201384.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"1175_CR19","doi-asserted-by":"publisher","first-page":"e0116377","DOI":"10.1371\/journal.pone.0116377","volume":"10","author":"ET Roberts","year":"2015","unstructured":"Roberts ET, Horne A, Martin SS, Blaha MJ, Blankstein R, Budoff MJ, et al. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One. 2015;10(3):e0116377.","journal-title":"PLoS One"},{"key":"1175_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/jn\/nxz020","volume":"149","author":"S Blanco Mejia","year":"2019","unstructured":"Blanco Mejia S, Messina M, Li SS, Viguiliouk E, Chiavaroli L, Khan TA, et al. A meta-analysis of 46 studies identified by the FDA demonstrates that soy protein decreases circulating LDL and total cholesterol concentrations in adults. J Nutr. 2019;149:968\u201381.","journal-title":"J Nutr"},{"issue":"Suppl 1","key":"1175_CR21","doi-asserted-by":"publisher","first-page":"320S","DOI":"10.3945\/ajcn.113.071431","volume":"100","author":"MA Martinez-Gonzalez","year":"2014","unstructured":"Martinez-Gonzalez MA, Sanchez-Tainta A, Corella D, Salas-Salvado J, Ros E, Aros F, et al. A provegetarian food pattern and reduction in total mortality in the Prevencion con Dieta Mediterranea (PREDIMED) study. Am J Clin Nutr. 2014;100(Suppl 1):320S\u20138S.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"1175_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/clc.22863","volume":"41","author":"RS Najjar","year":"2018","unstructured":"Najjar RS, Moore CE, Montgomery BD. A defined, plant-based diet utilized in an outpatient cardiovascular clinic effectively treats hypercholesterolemia and hypertension and reduces medications. Clin Cardiol. 2018;41(3):307\u201313.","journal-title":"Clin Cardiol"},{"issue":"23","key":"1175_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011367","volume":"7","author":"B Shah","year":"2018","unstructured":"Shah B, Newman JD, Woolf K, Ganguzza L, Guo Y, Allen N, et al. Anti-inflammatory effects of a vegan diet versus the American Heart Association-Recommended Diet in Coronary Artery Disease Trial. J Am Heart Assoc. 2018;7(23):e011367.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1175_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/nutrit\/nux030","volume":"75","author":"Y Yokoyama","year":"2017","unstructured":"Yokoyama Y, Levin SM, Barnard ND. Association between plant-based diets and plasma lipids: a systematic review and meta-analysis. Nutr Rev. 2017;75(9):683\u201398.","journal-title":"Nutr Rev"},{"issue":"18","key":"1175_CR25","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"C Emerging Risk Factors","year":"2009","unstructured":"Emerging Risk Factors C, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993\u20132000.","journal-title":"JAMA."},{"issue":"9753","key":"1175_CR26","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"CT Trialists","year":"2010","unstructured":"\u2022 Trialists CT. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381 This large meta-analysis demonstrated the safety and efficacy of further LDL-C lowering, without evidence of a threshold effect.","journal-title":"Lancet"},{"issue":"25","key":"1175_CR27","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1175_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/aje\/kwh237","volume":"160","author":"MA Austin","year":"2004","unstructured":"Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421\u20139.","journal-title":"Am J Epidemiol"},{"issue":"17","key":"1175_CR29","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","volume":"37","author":"M Benn","year":"2016","unstructured":"Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016;37(17):1384\u201394.","journal-title":"Eur Heart J"},{"issue":"9943","key":"1175_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(14)61009-6","volume":"384","author":"PM Ridker","year":"2014","unstructured":"Ridker PM. LDL cholesterol: controversies and future therapeutic directions. Lancet. 2014;384(9943):607\u201317.","journal-title":"Lancet."},{"issue":"32","key":"1175_CR31","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"\u2022\u2022 Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372 This wide-ranging analysis demonstrated the nearly incontrovertible causal relationship between LDL-C and ASCVD.","journal-title":"Eur Heart J"},{"issue":"21","key":"1175_CR32","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1056\/NEJMra1216063","volume":"368","author":"P Libby","year":"2013","unstructured":"Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004\u201313.","journal-title":"N Engl J Med"},{"issue":"20","key":"1175_CR33","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301\u20137.","journal-title":"N Engl J Med"},{"issue":"20","key":"1175_CR34","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615\u201322.","journal-title":"JAMA."},{"issue":"21","key":"1175_CR35","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021\u201331.","journal-title":"N Engl J Med"},{"issue":"8934","key":"1175_CR36","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study G","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study G. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383\u20139.","journal-title":"Lancet"},{"issue":"12","key":"1175_CR37","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289\u201397.","journal-title":"JAMA."},{"issue":"14","key":"1175_CR38","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785\u2013822.","journal-title":"J Am Coll Cardiol"},{"issue":"9784","key":"1175_CR39","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet."},{"issue":"25","key":"1175_CR40","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"\u2022 Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397 The IMPROVE-IT trial demonstrated the ability of a non-statin agent to both reduce LDL-C and recurrent ASCVD events in secondary prevention.","journal-title":"N Engl J Med"},{"issue":"18","key":"1175_CR41","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"\u2022 Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322 The FOURIER trial with the PCSK9 inhibitor evolocumab demonstrated the therapeutic role of these agents in secondary prevention.","journal-title":"N Engl J Med"},{"issue":"22","key":"1175_CR42","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"\u2022 Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107 The ODYSSEY trial with the PCSK9 inhibitor alirocumab demonstrated the therapeutic role of these agents in secondary prevention.","journal-title":"N Engl J Med"},{"issue":"15","key":"1175_CR43","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"\u2022 Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340 This large phase II trial of the siRNA molecule inclisiran demonstrated the tolerability and efficacy of this unique molecule in reducing LDL-C via the PCSK9 receptor.","journal-title":"N Engl J Med"},{"issue":"11","key":"1175_CR44","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"1175_CR45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977;62(5):707\u201314.","journal-title":"Am J Med"},{"issue":"1","key":"1175_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","volume":"79","author":"DJ Gordon","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8\u201315.","journal-title":"Circulation."},{"issue":"9943","key":"1175_CR47","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0140-6736(14)61217-4","volume":"384","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384(9943):618\u201325.","journal-title":"Lancet."},{"issue":"21","key":"1175_CR48","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","volume":"299","author":"R Frikke-Schmidt","year":"2008","unstructured":"Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524\u201332.","journal-title":"JAMA."},{"issue":"9","key":"1175_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","volume":"36","author":"MV Holmes","year":"2015","unstructured":"Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539\u201350.","journal-title":"Eur Heart J"},{"issue":"9841","key":"1175_CR50","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572\u201380.","journal-title":"Lancet."},{"issue":"3","key":"1175_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312.","journal-title":"N Engl J Med"},{"issue":"24","key":"1175_CR52","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"A-H Investigators","year":"2011","unstructured":"Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367.","journal-title":"N Engl J Med"},{"issue":"20","key":"1175_CR53","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933\u201342.","journal-title":"N Engl J Med"},{"issue":"22","key":"1175_CR54","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"21","key":"1175_CR55","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322.","journal-title":"N Engl J Med"},{"issue":"13","key":"1175_CR56","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"Group HTRC, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327.","journal-title":"N Engl J Med"},{"issue":"21","key":"1175_CR57","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1016\/j.jacc.2016.03.538","volume":"67","author":"P Mody","year":"2016","unstructured":"Mody P, Joshi PH, Khera A, Ayers CR, Rohatgi A. Beyond coronary calcification, family history, and C-reactive protein: cholesterol efflux capacity and cardiovascular risk prediction. J Am Coll Cardiol. 2016;67(21):2480\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"1175_CR58","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383\u201393.","journal-title":"N Engl J Med"},{"issue":"1","key":"1175_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11883-015-0554-1","volume":"18","author":"A Bhatt","year":"2016","unstructured":"Bhatt A, Rohatgi A. HDL cholesterol efflux capacity: cardiovascular risk factor and potential therapeutic target. Curr Atheroscler Rep. 2016;18(1):2.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"1175_CR60","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299\u2013308.","journal-title":"JAMA."},{"issue":"3","key":"1175_CR61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309\u201316.","journal-title":"JAMA."},{"issue":"7","key":"1175_CR62","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/eurheartj\/ehx659","volume":"39","author":"CM Madsen","year":"2018","unstructured":"Madsen CM, Varbo A, Nordestgaard BG. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology\/European Atherosclerosis Society guidelines: a contemporary population-based study. Eur Heart J. 2018;39(7):610\u20139.","journal-title":"Eur Heart J"},{"key":"1175_CR63","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345\u201352.","journal-title":"Nat Genet"},{"issue":"24","key":"1175_CR64","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","volume":"34","author":"AB Jorgensen","year":"2013","unstructured":"Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34(24):1826\u201333.","journal-title":"Eur Heart J"},{"issue":"8","key":"1175_CR65","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1210\/jc.2018-00470","volume":"103","author":"GA Nichols","year":"2018","unstructured":"Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;103(8):3019\u201327.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9943","key":"1175_CR66","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626\u201335.","journal-title":"Lancet."},{"issue":"16","key":"1175_CR67","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1161\/01.CIR.0000035280.64322.31","volume":"106","author":"HN Ginsberg","year":"2002","unstructured":"Ginsberg HN. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 2002;106(16):2137\u201342.","journal-title":"Circulation."},{"issue":"11","key":"1175_CR68","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345\u201361.","journal-title":"Eur Heart J"},{"issue":"13","key":"1175_CR69","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","volume":"36","author":"P Libby","year":"2015","unstructured":"Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2015;36(13):774\u20136.","journal-title":"Eur Heart J"},{"issue":"2","key":"1175_CR70","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","volume":"56","author":"AM Dattilo","year":"1992","unstructured":"Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320\u20138.","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"1175_CR71","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMcp070061","volume":"357","author":"JD Brunzell","year":"2007","unstructured":"Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007;357(10):1009\u201317.","journal-title":"N Engl J Med"},{"issue":"2","key":"1175_CR72","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/jama.1996.03530260042029","volume":"275","author":"RG Bakker-Arkema","year":"1996","unstructured":"Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275(2):128\u201333.","journal-title":"JAMA."},{"issue":"1","key":"1175_CR73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"\u2022 Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322 The REDUCE-IT trial demonstrated the added cardiovascular benefit of targeted triglyceride lowering with a highly purified fish-oil derivative named icosapent ethyl.","journal-title":"N Engl J Med"},{"issue":"11","key":"1175_CR74","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell TA 3rd, Fu W, Mullick AE, Alexander VJ, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479\u201390.","journal-title":"Circ Res"},{"issue":"6","key":"1175_CR75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MOL.0000000000000549","volume":"29","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S. RNA-targeted therapeutics for lipid disorders. Curr Opin Lipidol. 2018;29(6):459\u201366.","journal-title":"Curr Opin Lipidol"},{"issue":"13","key":"1175_CR76","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2174\/0929867324666170609081612","volume":"25","author":"J Schmitz","year":"2018","unstructured":"Schmitz J, Gouni-Berthold I. APOC-III antisense oligonucleotides: a new option for the treatment of hypertriglyceridemia. Curr Med Chem. 2018;25(13):1567\u201376.","journal-title":"Curr Med Chem"},{"issue":"4","key":"1175_CR77","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"C Emerging Risk Factors","year":"2009","unstructured":"Emerging Risk Factors C, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412\u201323.","journal-title":"JAMA."},{"issue":"2","key":"1175_CR78","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","volume":"117","author":"PR Kamstrup","year":"2008","unstructured":"Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176\u201384.","journal-title":"Circulation."},{"issue":"22","key":"1175_CR79","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331\u20139.","journal-title":"JAMA."},{"issue":"6","key":"1175_CR80","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","volume":"368","author":"G Thanassoulis","year":"2013","unstructured":"Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503\u201312.","journal-title":"N Engl J Med"},{"issue":"5","key":"1175_CR81","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"10155","key":"1175_CR82","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311\u201320.","journal-title":"Lancet."},{"issue":"2","key":"1175_CR83","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/00041433-200404000-00009","volume":"15","author":"ML Koschinsky","year":"2004","unstructured":"Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15(2):167\u201374.","journal-title":"Curr Opin Lipidol"},{"key":"1175_CR84","doi-asserted-by":"crossref","unstructured":"Berg K. A new serum type system in man\u2014the Lp system. 1963;59(3):369\u201382.","DOI":"10.1111\/j.1699-0463.1963.tb01808.x"},{"key":"1175_CR85","volume-title":"Clinical lipidology: a companion to Braunwald\u2019s heart disease","author":"CM Ballantyne","year":"2015","unstructured":"Ballantyne CM. Clinical lipidology: a companion to Braunwald\u2019s heart disease. Philadelphia: 2nd edition; 2015."},{"issue":"1","key":"1175_CR86","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","volume":"90","author":"E Boerwinkle","year":"1992","unstructured":"Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52\u201360.","journal-title":"J Clin Invest"},{"issue":"6","key":"1175_CR87","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1172\/JCI117292","volume":"93","author":"DJ Rader","year":"1994","unstructured":"Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994;93(6):2758\u201363.","journal-title":"J Clin Invest"},{"issue":"26","key":"1175_CR88","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"17","key":"1175_CR89","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.117.031356","volume":"138","author":"W-Q Wei","year":"2018","unstructured":"Wei W-Q, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, et al. LPA variants are associated with residual cardiovascular risk in patients receiving statins. Circulation. 2018;138(17):1839\u201349.","journal-title":"Circulation."},{"issue":"3","key":"1175_CR90","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","volume":"72","author":"NR Cook","year":"2018","unstructured":"Cook NR, Mora S, Ridker PM. Lipoprotein(a) and cardiovascular risk prediction among women. J Am Coll Cardiol. 2018;72(3):287\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1175_CR91","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","volume":"139","author":"G Par\u00e9","year":"2019","unstructured":"Par\u00e9 G, \u00c7aku A, McQueen M, Anand Sonia S, Enas E, Clarke R, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139(12):1472\u201382.","journal-title":"Circulation."},{"issue":"5","key":"1175_CR92","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","volume":"36","author":"J Cao","year":"2016","unstructured":"Cao J, Steffen BT, Budoff M, Post WS, Thanassoulis G, Kestenbaum B, et al. Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in White and Black individuals: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36(5):1003\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1175_CR93","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","volume":"125","author":"SS Virani","year":"2012","unstructured":"Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in Black and White subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125(2):241\u20139.","journal-title":"Circulation."},{"issue":"4","key":"1175_CR94","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","volume":"35","author":"W Guan","year":"2015","unstructured":"Guan W, Cao J, Steffen BT, Post WS, Stein JH, Tattersall MC, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35(4):996\u20131001.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"1175_CR95","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J"},{"issue":"12","key":"1175_CR96","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1161\/CIRCULATIONAHA.119.038989","volume":"139","author":"G Thanassoulis","year":"2019","unstructured":"Thanassoulis G. Screening for high lipoprotein(a). Circulation. 2019;139(12):1493\u20136.","journal-title":"Circulation."},{"issue":"9","key":"1175_CR97","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","volume":"64","author":"P Willeit","year":"2014","unstructured":"Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64(9):851\u201360.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1175_CR98","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"\u2022\u2022 Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692\u2013711 This comprehensive review of lipoprotein(a) and cardiovascular disease synthesizes important insights into the lipoprotein(a) and its future as a therapeutic target.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1175_CR99","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"\u2022 O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483\u201392 This analysis of the FOURIER trial demonstrated that the PCSK9 inhibitor evolocumab reduced the risk of major cardiovascular events by a greater degree in patients with an elevated Lp(a) as compared with those with Lp(a) levels below the median. This analysis supported Lp(a) as a modifiable risk factor and provides insight into which patients may benefit the most from PCSK9 inhibition.","journal-title":"Circulation"},{"issue":"1","key":"1175_CR100","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJMra1705346","volume":"380","author":"AA Levin","year":"2019","unstructured":"Levin AA. Treating disease at the RNA level with oligonucleotides. N Engl J Med. 2019;380(1):57\u201370.","journal-title":"N Engl J Med"},{"issue":"10057","key":"1175_CR101","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388(10057):2239\u201353.","journal-title":"Lancet."},{"issue":"10002","key":"1175_CR102","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386(10002):1472\u201383.","journal-title":"Lancet."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1175-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-019-1175-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1175-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T06:05:12Z","timestamp":1650175512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-019-1175-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":102,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1175-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]},"assertion":[{"value":"5 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Adam Berman declares that he has no conflict of interest.Ron Blankstein reports grants from Astellas Inc. and Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"110"}}